GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merrimack Pharmaceuticals Inc (NAS:MACK) » Definitions » Accounts Payable & Accrued Expense

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Accounts Payable & Accrued Expense : $0.25 Mil (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Merrimack Pharmaceuticals Accounts Payable & Accrued Expense?

Merrimack Pharmaceuticals's quarterly accounts payable & accrued expense increased from Jun. 2023 ($0.22 Mil) to Sep. 2023 ($0.30 Mil) but then declined from Sep. 2023 ($0.30 Mil) to Dec. 2023 ($0.25 Mil).

Merrimack Pharmaceuticals's annual accounts payable & accrued expense increased from Dec. 2021 ($0.37 Mil) to Dec. 2022 ($0.40 Mil) but then declined from Dec. 2022 ($0.40 Mil) to Dec. 2023 ($0.25 Mil).


Merrimack Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for Merrimack Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merrimack Pharmaceuticals Accounts Payable & Accrued Expense Chart

Merrimack Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.40 0.43 0.37 0.40 0.25

Merrimack Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.27 0.22 0.30 0.25

Merrimack Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.


Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
One Broadway, 14th Floor, Cambridge, MA, USA, 02142
Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.
Executives
Eric Andersen director, other: See Remarks 1507 BERKELEY ST, SUITE 7, SANTA MONICA X1 90404
Gary L Crocker director, officer: President MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Noah G. Levy director, other: See Remarks 60 EAST 42ND ST, 9TH FLOOR, NEW YORK NY 10165
Ana Radeljevic director 2430 BEACON STREET, UNIT 201, CHESTNUT HILL MA 02467
Ulrik B. Nielsen director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Russell T Ray director 2525 DUPONT DR, IRVINE CA 92612
Newtyn Capital Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Ledo Capital, Llc other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Te Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Western Standard Partners Qp, L.p. other: See Remarks 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Partners Lp other: See Remarks 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Llc other: See Remarks 5757 WILSHIRE BLVD, SUITE 636, LOS ANGELES CA 90036
Newtyn Management, Llc other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
22nw Gp, Inc. 10 percent owner, other: See Explanation of Responses 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Headlines

From GuruFocus

Merrimack Reports Full Year 2021 Financial Results

By Business Wire Business Wire 03-09-2022

Steven Cohen Buys 4, Sells 1 in 2nd Quarter

By GuruFocus Research GuruFocus Editor 08-15-2022

Merrimack Reports First Quarter 2020 Financial Results

By Business Wire Business Wire 05-08-2020

Merrimack Reports Third Quarter 2021 Financial Results

By Business Wire Business Wire 11-04-2021

Merrimack Reports First Quarter 2022 Financial Results

By Business Wire Business Wire 05-05-2022

Merrimack Reports Second Quarter 2022 Financial Results

By Business Wire Business Wire 08-04-2022